NASDAQ: LTRN - Lantern Pharma Inc.

六个月盈利: -22.27%
股息率: 0.00%
部门: Healthcare

促销时间表 Lantern Pharma Inc.

先进的时间表 简单图表
Financial Markets by TradingView

关于公司 Lantern Pharma Inc.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma.

更多详情
In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

IPO date 2020-06-11
ISIN US51654W1018
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.lanternpharma.com
Цена ао 10.03
每日价格变化: -2.84% (3.52)
每周价格变化: +8.74% (3.145)
每月价格变化: +9.97% (3.11)
3个月内价格变化: -9.4% (3.775)
六个月内的价格变化: -22.27% (4.4)
每年价格变化: -20.09% (4.28)
3年内价格变化: -53.41% (7.34)
5年内价格变化: 0% (3.42)
10年价格变化: 0% (3.42)
年初以来价格变化: +11.04% (3.08)
所有参数

低估

姓名 意义 年级
P/S 0 0
P/BV 1.08 9
P/E 0 0
EV/EBITDA -1.27 0
全部的: 3.63

效率

姓名 意义 年级
ROA, % -36.57 0
ROE, % -39.02 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.0132 10
全部的: 7.8

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 0 0
盈利能力 Ebitda, % 557.78 10
盈利能力 EPS, % 276.99 10
全部的: 8
更多详情

机构 体积 分享, %
Vanguard Group Inc 365334 3.4
NewEdge Advisors, LLC 165972 1.55
Geode Capital Management, LLC 95036 0.88
CM Management, LLC 80000 0.74
Carlson Capital. L.P. 60000 0.56
Commonwealth Equity Services, LLC 58848 0.55
Renaissance Technologies, LLC 43800 0.41
Redmond Asset Management, LLC 40662 0.38
Horizon Kinetics Asset Management LLC 28791 0.27
State Street Corporation 27752 0.26

ETF 分享, % 本年盈利能力, % 股息, %
iShares Micro-Cap ETF 0.00743 17.09 1.54048
Dimensional U.S. Targeted Value ETF 0.00011 26.01 1.93487
Dimensional U.S. Core Equity 2 ETF 0.00006 30.76 1.47098



导师 职称 支付 出生年份
Mr. Panna Sharma PH.D. President, CEO & Director 684.38k 1971 (54 年)
Mr. David R. Margrave CFO & Secretary 442.68k 1961 (64 年)
Dr. Kishor Gopaldas Bhatia Ph.D. Chief Scientific Officer & Scientific Consultant 283.24k 1955 (70 年)
Nicole Leber Investor Relations Associate, Finance & Administrative Coordinator N/A
Dr. Peter L. Nara D.V.M., M.S., Ph.D. Co-Founder & Advisor N/A
Mr. Ernest Kitt B.S., M.S Head of Clinical Operations N/A
Dr. Marc C. Chamberlain M.D. Chief Medical Officer of Starlight Therapeutics

地址: United States, Dallas. TX, 1920 McKinney Avenue - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.lanternpharma.com